Skip to main content


You are here Baltimore: UMB grants licensing option for anticancer drug that uses Anthrax

Thursday, September 19, 2019

The agreement is with Spherix Incorporated, whose CEO called the drug "ingenious."

New York-based Spherix Incorporated announced a licensing agreement this week for a University of Maryland, Baltimore-invented drug that reengineered Anthrax to treat ovarian cancer.

Spherix was granted an exclusive option to license the drug, called PrAg-PAS, from the university. Under this option, Spherix has until December to complete due diligence and execute a license to commercially develop the drug.

Read the full story from Baltimore.